$0.14
(Market cap
$-- Mln
Recently Viewed
Clear AllMarket cap
$-- Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-- Mln
ROE
-2.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-6.3
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
39,529,847
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tharimmune Inc Forgn. Eq (THAR)
| 8.3 | -26.8 | 9.0 | 180.3 | -77.6 | -- | -- |
|
BSE Sensex*
| -9.5 | -2.9 | -9.0 | 3.2 | 8.6 | 9.0 | 12.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
Tharimmune Inc Forgn. Eq (THAR)
| 49.3 | -73.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 |
|
BSE Sensex
| 9.1 | 8.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tharimmune Inc Forgn. Eq (THAR)
|
3.3 | 187.4 | 0.0 | -35.9 | -- | -18 | -- | 0.4 |
|
Tharimmune Inc Forgn. Eq (THAR)
|
3.3 | 187.4 | 0.0 | -35.9 | -- | -18 | -- | 0.4 |
| 64.4 | 8,558.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.2 | 15.0 | |
| 65.8 | 7,998.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 44.2 | 11,791.6 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 92.8 | 11,760.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,473.4 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.6 | 156.5 | |
| 519.8 | 12,247.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 520.7 | 14,077.1 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.5 | 30.8 | |
| 105.0 | 8,153.4 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 320.2 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development... activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was founded in 2017 and is based in Red Bank, New Jersey. Read more
President, Chairman & CEO
Mr. Randy D. Milby MBA
President, Chairman & CEO
Mr. Randy D. Milby MBA
Headquarters
--
Website
--
Our rating system has guided millions of investors in the past 20 years.
The share price of Tharimmune Inc Forgn Eq (THAR) is $3.28 (NASDAQ) as of 08-Apr-2026 09:30 EDT. Tharimmune Inc Forgn Eq (THAR) has given a return of -77.62% in the last 3 years.
Since, TTM earnings of Tharimmune Inc Forgn Eq (THAR) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
-0.17
|
1.55
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Tharimmune Inc Forgn Eq (THAR) are Rs -- and Rs -- as of 09-Apr-2026.
Before investing in Tharimmune Inc Forgn Eq (THAR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.